BCIQ Profiles

Company Profile Report

Shire HAE treatment from Dyax deal clears Phase III hurdle

Shire plc (LSE:SHP; NASDAQ:SHPG) will submit a BLA to FDA by early next year for subcutaneous lanadelumab (SHP643) to prevent hereditary angioedema (HAE) attacks after the compound met the primary endpoint in the

Read the full 335 word article

How to gain access

Continue reading with a
two-week free trial.